Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Employing Mesenchymal Stromal Cells (MSC) for Managing Acute and Chronic Graft-versus-Host-Disease

Version 1 : Received: 11 February 2023 / Approved: 14 February 2023 / Online: 14 February 2023 (08:39:01 CET)

How to cite: Mendiratta, M.; Mendiratta, M.; Mohanty, S.; Sahoo, R.K.; Prakash, H. Employing Mesenchymal Stromal Cells (MSC) for Managing Acute and Chronic Graft-versus-Host-Disease. Preprints 2023, 2023020240. https://doi.org/10.20944/preprints202302.0240.v1. Mendiratta, M.; Mendiratta, M.; Mohanty, S.; Sahoo, R.K.; Prakash, H. Employing Mesenchymal Stromal Cells (MSC) for Managing Acute and Chronic Graft-versus-Host-Disease. Preprints 2023, 2023020240. https://doi.org/10.20944/preprints202302.0240.v1.

Abstract

Mesenchymal Stromal Cells (MSCs) are multipotent, non-hematopoietic progenitor cells with a wide range of immune conditioning and regenerative potential which qualify them as potential component of cell based therapy for various autoimmune / chronic inflammatory ailments. Their immunomodulatory properties include the secretion of immunosuppressive cytokines, the ability to suppress T-cell activation and differentiation, and the induction of regulatory T-cells. In view of this and our interest, we here discuss the significance of MSC for the management of Graft-versus-Host Disease (aGVHD), one of the autoimmune manifestation in human.. In pre-clinical models, MSCs have been shown to reduce the severity of aGVHD symptoms, including skin and gut damage, which are the most common and debilitating manifestations of this disease. While initial clinical studies of MSCs in aGVHD cases were promising, the results were variable in randomized studies. So, further studies are warranted to fully understand their potential benefits, safety profile, and optimal dosing regimens. In view of these inevitable issues, here we discuss various mechanisms, how MSCs can be employed in managing aGVHD, as a therapeutic option for this disease.

Keywords

Mesenchymal Stromal Cells; Graft-versus-Host-Disease; Immunomodulation; Apoptosis; Efferocytosis; Secretome

Subject

MEDICINE & PHARMACOLOGY, Oncology & Oncogenics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.